Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Purchased by Mirador Capital Partners LP

Mirador Capital Partners LP boosted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,526 shares of the medical equipment provider’s stock after buying an additional 50 shares during the quarter. Mirador Capital Partners LP’s holdings in Intuitive Surgical were worth $1,732,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Goelzer Investment Management Inc. increased its stake in shares of Intuitive Surgical by 0.6% in the 3rd quarter. Goelzer Investment Management Inc. now owns 6,321 shares of the medical equipment provider’s stock valued at $3,105,000 after purchasing an additional 39 shares in the last quarter. HBW Advisory Services LLC purchased a new stake in shares of Intuitive Surgical in the third quarter valued at approximately $235,000. MRA Advisory Group lifted its position in shares of Intuitive Surgical by 28.7% during the 3rd quarter. MRA Advisory Group now owns 959 shares of the medical equipment provider’s stock valued at $471,000 after buying an additional 214 shares in the last quarter. Czech National Bank grew its stake in Intuitive Surgical by 6.9% in the 3rd quarter. Czech National Bank now owns 72,257 shares of the medical equipment provider’s stock valued at $35,498,000 after acquiring an additional 4,665 shares during the period. Finally, Massmutual Trust Co. FSB ADV raised its position in Intuitive Surgical by 8.5% during the third quarter. Massmutual Trust Co. FSB ADV now owns 1,148 shares of the medical equipment provider’s stock worth $564,000 after acquiring an additional 90 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Shares of ISRG stock traded up $2.32 on Friday, hitting $481.95. The stock had a trading volume of 903,893 shares, compared to its average volume of 1,479,332. The company’s 50 day moving average price is $476.55 and its 200-day moving average price is $431.54. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $496.48. The firm has a market capitalization of $170.95 billion, a P/E ratio of 86.99, a P/E/G ratio of 5.39 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.18 EPS. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of Intuitive Surgical stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $446.60, for a total transaction of $167,921.60. Following the completion of the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,458,979.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of the company’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $446.60, for a total value of $167,921.60. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,458,979.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Amy L. Ladd sold 450 shares of Intuitive Surgical stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the sale, the director now owns 821 shares in the company, valued at $402,519.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 53,120 shares of company stock valued at $25,528,753 in the last quarter. Corporate insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ISRG. Stifel Nicolaus increased their target price on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a report on Friday, July 19th. Evercore ISI raised their price objective on Intuitive Surgical from $410.00 to $475.00 and gave the company an “in-line” rating in a report on Tuesday. BTIG Research upped their target price on shares of Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Morgan Stanley increased their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Finally, Robert W. Baird upped their price objective on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research note on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $449.70.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.